179 related articles for article (PubMed ID: 8862724)
1. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
Hasinoff BB; Yalowich JC; Ling Y; Buss JL
Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
[TBL] [Abstract][Full Text] [Related]
2. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
3. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
[TBL] [Abstract][Full Text] [Related]
4. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
6. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells.
Malisza KL; Hasinoff BB
Free Radic Biol Med; 1996; 20(7):905-14. PubMed ID: 8743977
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Langer SW; Sehested M; Jensen PB
Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
[TBL] [Abstract][Full Text] [Related]
10. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
[TBL] [Abstract][Full Text] [Related]
11. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site.
Hasinoff BB; Creighton AM; Kozlowska H; Thampatty P; Allan WP; Yalowich JC
Mol Pharmacol; 1997 Nov; 52(5):839-45. PubMed ID: 9351975
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
13. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane (ICRF-187).
Weiss G; Loyevsky M; Gordeuk VR
Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
[TBL] [Abstract][Full Text] [Related]
16. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
17. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
18. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
19. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
[TBL] [Abstract][Full Text] [Related]
20. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]